LLY

917.82

+3.36%↑

JNJ

243.26

+0.5%↑

ABBV

216.83

+1.6%↑

NVS

151.64

+0.81%↑

MRK

119.41

+1.21%↑

LLY

917.82

+3.36%↑

JNJ

243.26

+0.5%↑

ABBV

216.83

+1.6%↑

NVS

151.64

+0.81%↑

MRK

119.41

+1.21%↑

LLY

917.82

+3.36%↑

JNJ

243.26

+0.5%↑

ABBV

216.83

+1.6%↑

NVS

151.64

+0.81%↑

MRK

119.41

+1.21%↑

LLY

917.82

+3.36%↑

JNJ

243.26

+0.5%↑

ABBV

216.83

+1.6%↑

NVS

151.64

+0.81%↑

MRK

119.41

+1.21%↑

LLY

917.82

+3.36%↑

JNJ

243.26

+0.5%↑

ABBV

216.83

+1.6%↑

NVS

151.64

+0.81%↑

MRK

119.41

+1.21%↑

Home・Akciju saraksts・ResMed Inc

ResMed Inc

Atvērts

SektorsVeselības aprūpe

224.03 1.8

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

218.73

Max

224.6

Galvenie mērījumi
By Trading Economics
Ienākumi	44M 393M
Pārdošana	87M 1.4B
P/E Sektora vidējais	22.571 57.05
Dividenžu ienesīgums	1
Peļņas marža	27.593
Darbinieki	10,600
EBITDA	63M 566M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt
Prognoze 12 mēnešiem	+34.35% upside

Dividendes
By Dow Jones
Dividenžu ienesīgums Sektora vidējais	1.00% 2.52%
Nākamie ieņēmumi	2026. g. 22. apr.
Nākamais dividenžu datums	2026. g. 11. jūn.
Nākamais Ex dividenžu datums	2026. g. 7. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	-4B 33B
Iepriekšējā atvēršanas cena	222.23
Iepriekšējā slēgšanas cena	224.03

Ziņu noskaņojums

By Acuity

27%

73%

83 / 349 Rangs Healthcare

ResMed Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 30. marts 23:15 UTC

Galvenie ziņu notikumi

U.K. Shoppers Paid a Little More This Month But Worse May yet Lie Ahead

2026. g. 30. marts 22:36 UTC

Galvenie ziņu notikumi

Australian Government Rules Out Boots on the Ground in the Middle East

2026. g. 30. marts 22:13 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life Financial Agrees to Buy Bell Partners for $350 Million

2026. g. 30. marts 21:00 UTC

Peļņas

Aktis Oncology Gets FDA Clearance for Phase 1 Billion Trial of Tumor Treatment

2026. g. 30. marts 20:15 UTC

Galvenie ziņu notikumi

Fed's Williams: Middle-East Developments Have Added Significant Economic Uncertainty

2026. g. 30. marts 23:40 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 30. marts 23:40 UTC

Tirgus saruna

Nikkei May Decline on Higher Energy Cost Concerns -- Market Talk

2026. g. 30. marts 23:36 UTC

Tirgus saruna

Gold Edges Lower Amid Divergent Signals on U.S.-Iran Talks -- Market Talk

2026. g. 30. marts 23:12 UTC

Tirgus saruna

Alcoa Earnings Outlook Boosted by Market Disruptions -- Market Talk

2026. g. 30. marts 22:49 UTC

Tirgus saruna

Fed's Williams: Core Inflation Forecast Is Little Changed -- Market Talk

2026. g. 30. marts 22:44 UTC

Tirgus saruna

Fed's Williams: Risks to Both Sides of Dual Mandate Higher -- Market Talk

2026. g. 30. marts 22:43 UTC

Tirgus saruna

Fed's Williams Says Focus Is on Inflation Expectations Being Well Anchored -- Market Talk

2026. g. 30. marts 22:42 UTC

Tirgus saruna

South32 Should Go for Growth, Says New Bull -- Market Talk

2026. g. 30. marts 22:18 UTC

Tirgus saruna

Paragon Care's Chances of Using Levy to Pass on Higher Costs `Close to Zero' -- Market Talk

2026. g. 30. marts 22:05 UTC

Tirgus saruna

Northern Star's New Bull Argues Case for Asset Sales -- Market Talk

2026. g. 30. marts 21:58 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life Financial Agrees to Buy Bell Partners for $350M

2026. g. 30. marts 21:39 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life Sees 1Q Charge to Net of C$236M From BGO, Crescent Deals

2026. g. 30. marts 21:38 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life: Completes Remaining Equity Interest Purchases of BGO, Crescent Capital

2026. g. 30. marts 21:36 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life to Buy Fully Bell Partners for $350M >SLF.T

2026. g. 30. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Unilever Shareholders Expected to Own Two-Thirds of New Food Entity, Sources Say -- WSJ

2026. g. 30. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Unilever Nears Deal to Create $60 Billion Food Giant With McCormick -- WSJ

2026. g. 30. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Deal Could Be Announced As Soon As Tuesday, Sources Say -- WSJ

2026. g. 30. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Unilever Nears Cash-and-Stock Deal to Combine Food Business With McCormick, Sources Say -- WSJ

2026. g. 30. marts 21:33 UTC

Iegādes, apvienošanās, pārņemšana

Deal Set to Value Combined Food Business At Around $60B Including Debt, Sources Say -- WSJ

2026. g. 30. marts 21:25 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 30. marts 21:25 UTC

Tirgus saruna

Warehouse Showing Cost Discipline But Margin Goal at Risk -- Market Talk

2026. g. 30. marts 21:03 UTC

Iegādes, apvienošanās, pārņemšana

Sun Life: Completes Equity Interest Purchases of BGO and Crescent Cap, Announces Acquisition of Bell Partners, a Multifamily Real Estate Investment Manager

2026. g. 30. marts 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 30. marts 20:09 UTC

Peļņas

This Stock Looks Like a Solid AI Bet -- and Wall Street Hasn't Noticed Yet -- Barrons.com

2026. g. 30. marts 20:00 UTC

Galvenie ziņu notikumi

Fed's Williams: Middle-East Conflict 'Will Likely Boost Overall Inflation in Coming Months'

Salīdzinājums

Cenas izmaiņa

ResMed Inc Prognoze

Cenas mērķis

By TipRanks

34.35% augšup

Prognoze 12 mēnešiem

Vidējais 296.2 USD 34.35%

Augstākais 345 USD

Zemākais 265 USD

Pamatojoties uz 12 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi ResMed Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

12 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 12 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam ResMed Inc — pēdējo 3 mēnešu laikā.

Noskaņojums

By Acuity

83 / 349 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par ResMed Inc

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.